APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Primary Biliary Cirrhosis Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Primary Biliary Cirrhosis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174028490319 December 2025191 pages

Choose your research edition.

Industry ResearchPrimary Biliary Cirrhosis Drug Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Primary Biliary Cirrhosis Drug Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Primary Biliary Cirrhosis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Primary Biliary Cirrhosis Drug Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Primary Biliary Cirrhosis Drug Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Primary Biliary Cirrhosis Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Primary Biliary Cirrhosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Primary Biliary Cirrhosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Primary Biliary Cirrhosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Primary Biliary Cirrhosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Primary Biliary Cirrhosis Drug include AlbireoPharma, CymaBay Therapeutics, Inc., Dr. Falk Pharma GmbH, Enanta Pharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., MediGene AG, NGM Biopharmaceuticals, Inc., Virobay Inc. and GlaxoSmithKline Plc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Primary Biliary Cirrhosis Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Primary Biliary Cirrhosis Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Primary Biliary Cirrhosis Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Primary Biliary Cirrhosis Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Primary Biliary Cirrhosis Drug Segment by Company

AlbireoPharma

CymaBay Therapeutics, Inc.

Dr. Falk Pharma GmbH

Enanta Pharmaceuticals, Inc.

Intercept Pharmaceuticals, Inc.

MediGene AG

NGM Biopharmaceuticals, Inc.

Virobay Inc.

GlaxoSmithKline Plc

Johnson & Johnson

Primary Biliary Cirrhosis Drug Segment by Type

Budesonide

NGM-282

MBX-8025

GSK-2330672

FFP-104

Others

Primary Biliary Cirrhosis Drug Segment by Application

Clinic

Hospital

Others

Primary Biliary Cirrhosis Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Primary Biliary Cirrhosis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Primary Biliary Cirrhosis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Primary Biliary Cirrhosis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Primary Biliary Cirrhosis Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Primary Biliary Cirrhosis Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Primary Biliary Cirrhosis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Primary Biliary Cirrhosis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Primary Biliary Cirrhosis Drug Industry Trends Table 2. Primary Biliary Cirrhosis Drug Industry Drivers Table 3. Primary Biliary Cirrhosis Drug Industry Opportunities and Challenges Table 4. Primary Biliary Cirrhosis Drug Industry Restraints Table 5. Global Primary Biliary Cirrhosis Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Primary Biliary Cirrhosis Drug Sales by Manufacturers (W Units) & (2021-2026) Table 8. Global Primary Biliary Cirrhosis Drug Sales Market Share by Manufacturers Table 9. Global Primary Biliary Cirrhosis Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Primary Biliary Cirrhosis Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Primary Biliary Cirrhosis Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Primary Biliary Cirrhosis Drug Manufacturers, Product Type & Application Table 13. Global Primary Biliary Cirrhosis Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Primary Biliary Cirrhosis Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Budesonide Table 17. Major Manufacturers of NGM-282 Table 18. Major Manufacturers of MBX-8025 Table 19. Major Manufacturers of GSK-2330672 Table 20. Major Manufacturers of FFP-104 Table 21. Major Manufacturers of Others Table 22. Global Primary Biliary Cirrhosis Drug Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 23. Global Primary Biliary Cirrhosis Drug Sales by Type (2021-2026) & (W Units) Table 24. Global Primary Biliary Cirrhosis Drug Sales by Type (2027-2032) & (W Units) Table 25. Global Primary Biliary Cirrhosis Drug Sales Market Share by Type (2021-2026) Table 26. Global Primary Biliary Cirrhosis Drug Sales Market Share by Type (2027-2032) Table 27. Global Primary Biliary Cirrhosis Drug Revenue by Type 2021 VS 2025 VS 2032 (W Units) Table 28. Global Primary Biliary Cirrhosis Drug Revenue by Type (2021-2026) & (W Units) Table 29. Global Primary Biliary Cirrhosis Drug Revenue by Type (2027-2032) & (W Units) Table 30. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Type (2021-2026) Table 31. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Clinic Table 33. Major Manufacturers of Hospital Table 34. Major Manufacturers of Others Table 35. Global Primary Biliary Cirrhosis Drug Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 36. Global Primary Biliary Cirrhosis Drug Sales by Application (2021-2026) & (W Units) Table 37. Global Primary Biliary Cirrhosis Drug Sales by Application (2027-2032) & (W Units) Table 38. Global Primary Biliary Cirrhosis Drug Sales Market Share by Application (2021-2026) Table 39. Global Primary Biliary Cirrhosis Drug Sales Market Share by Application (2027-2032) Table 40. Global Primary Biliary Cirrhosis Drug Revenue by Application 2021 VS 2025 VS 2032 (W Units) Table 41. Global Primary Biliary Cirrhosis Drug Revenue by Application (2021-2026) & (W Units) Table 42. Global Primary Biliary Cirrhosis Drug Revenue by Application (2027-2032) & (W Units) Table 43. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Application (2021-2026) Table 44. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Application (2027-2032) Table 45. Global Primary Biliary Cirrhosis Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 46. Global Primary Biliary Cirrhosis Drug Sales by Region (2021-2026) & (W Units) Table 47. Global Primary Biliary Cirrhosis Drug Sales Market Share by Region (2021-2026) Table 48. Global Primary Biliary Cirrhosis Drug Sales Forecasted by Region (2027-2032) & (W Units) Table 49. Global Primary Biliary Cirrhosis Drug Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Primary Biliary Cirrhosis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 51. North America Primary Biliary Cirrhosis Drug Sales by Country (2021-2026) & (W Units) Table 52. North America Primary Biliary Cirrhosis Drug Sales by Country (2027-2032) & (W Units) Table 53. Europe Primary Biliary Cirrhosis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 54. Europe Primary Biliary Cirrhosis Drug Sales by Country (2021-2026) & (W Units) Table 55. Europe Primary Biliary Cirrhosis Drug Sales by Country (2027-2032) & (W Units) Table 56. Asia Pacific Primary Biliary Cirrhosis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 57. Asia Pacific Primary Biliary Cirrhosis Drug Sales by Country (2021-2026) & (W Units) Table 58. Asia Pacific Primary Biliary Cirrhosis Drug Sales by Country (2027-2032) & (W Units) Table 59. South America, Middle East and Africa Primary Biliary Cirrhosis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 60. South America, Middle East and Africa Primary Biliary Cirrhosis Drug Sales by Country (2021-2026) & (W Units) Table 61. South America, Middle East and Africa Primary Biliary Cirrhosis Drug Sales by Country (2027-2032) & (W Units) Table 62. Global Primary Biliary Cirrhosis Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Primary Biliary Cirrhosis Drug Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Primary Biliary Cirrhosis Drug Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Region (2021-2026) Table 66. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Region (2027-2032) Table 67. AlbireoPharma Company Information Table 68. AlbireoPharma Business Overview Table 69. AlbireoPharma Primary Biliary Cirrhosis Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. AlbireoPharma Primary Biliary Cirrhosis Drug Product Portfolio Table 71. AlbireoPharma Recent Development Table 72. CymaBay Therapeutics, Inc. Company Information Table 73. CymaBay Therapeutics, Inc. Business Overview Table 74. CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Product Portfolio Table 76. CymaBay Therapeutics, Inc. Recent Development Table 77. Dr. Falk Pharma GmbH Company Information Table 78. Dr. Falk Pharma GmbH Business Overview Table 79. Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Product Portfolio Table 81. Dr. Falk Pharma GmbH Recent Development Table 82. Enanta Pharmaceuticals, Inc. Company Information Table 83. Enanta Pharmaceuticals, Inc. Business Overview Table 84. Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Portfolio Table 86. Enanta Pharmaceuticals, Inc. Recent Development Table 87. Intercept Pharmaceuticals, Inc. Company Information Table 88. Intercept Pharmaceuticals, Inc. Business Overview Table 89. Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Portfolio Table 91. Intercept Pharmaceuticals, Inc. Recent Development Table 92. MediGene AG Company Information Table 93. MediGene AG Business Overview Table 94. MediGene AG Primary Biliary Cirrhosis Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. MediGene AG Primary Biliary Cirrhosis Drug Product Portfolio Table 96. MediGene AG Recent Development Table 97. NGM Biopharmaceuticals, Inc. Company Information Table 98. NGM Biopharmaceuticals, Inc. Business Overview Table 99. NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Portfolio Table 101. NGM Biopharmaceuticals, Inc. Recent Development Table 102. Virobay Inc. Company Information Table 103. Virobay Inc. Business Overview Table 104. Virobay Inc. Primary Biliary Cirrhosis Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Virobay Inc. Primary Biliary Cirrhosis Drug Product Portfolio Table 106. Virobay Inc. Recent Development Table 107. GlaxoSmithKline Plc Company Information Table 108. GlaxoSmithKline Plc Business Overview Table 109. GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Product Portfolio Table 111. GlaxoSmithKline Plc Recent Development Table 112. Johnson & Johnson Company Information Table 113. Johnson & Johnson Business Overview Table 114. Johnson & Johnson Primary Biliary Cirrhosis Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Johnson & Johnson Primary Biliary Cirrhosis Drug Product Portfolio Table 116. Johnson & Johnson Recent Development Table 117. Key Raw Materials Table 118. Raw Materials Key Suppliers Table 119. Primary Biliary Cirrhosis Drug Distributors List Table 120. Primary Biliary Cirrhosis Drug Customers List Table 121. Research Programs/Design for This Report Table 122. Authors List of This Report Table 123. Secondary Sources Table 124. Primary Sources List of Figures Figure 1. Primary Biliary Cirrhosis Drug Product Image Figure 2. Global Primary Biliary Cirrhosis Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Primary Biliary Cirrhosis Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Primary Biliary Cirrhosis Drug Sales (2021-2032) & (W Units) Figure 5. Global Primary Biliary Cirrhosis Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Primary Biliary Cirrhosis Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Budesonide Image Figure 9. NGM-282 Image Figure 10. MBX-8025 Image Figure 11. GSK-2330672 Image Figure 12. FFP-104 Image Figure 13. Others Image Figure 14. Global Primary Biliary Cirrhosis Drug Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 15. Global Primary Biliary Cirrhosis Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Primary Biliary Cirrhosis Drug Sales Market Share by Type (2021-2032) Figure 17. Global Primary Biliary Cirrhosis Drug Revenue by Type (2021 VS 2025 VS 2032) & (W Units) Figure 18. Global Primary Biliary Cirrhosis Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Type (2021-2032) Figure 20. Clinic Image Figure 21. Hospital Image Figure 22. Others Image Figure 23. Global Primary Biliary Cirrhosis Drug Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 24. Global Primary Biliary Cirrhosis Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Primary Biliary Cirrhosis Drug Sales Market Share by Application (2021-2032) Figure 26. Global Primary Biliary Cirrhosis Drug Revenue by Application (2021 VS 2025 VS 2032) & (W Units) Figure 27. Global Primary Biliary Cirrhosis Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Application (2021-2032) Figure 29. North America Primary Biliary Cirrhosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 30. North America Primary Biliary Cirrhosis Drug Sales Market Share by Country (2021-2032) Figure 31. U.S. Primary Biliary Cirrhosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 32. Canada Primary Biliary Cirrhosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 33. Mexico Primary Biliary Cirrhosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 34. Europe Primary Biliary Cirrhosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 35. Europe Primary Biliary Cirrhosis Drug Sales Market Share by Country (2021-2032) Figure 36. Germany Primary Biliary Cirrhosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 37. France Primary Biliary Cirrhosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 38. U.K. Primary Biliary Cirrhosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 39. Italy Primary Biliary Cirrhosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 40. Netherlands Primary Biliary Cirrhosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 41. Asia Pacific Primary Biliary Cirrhosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 42. Asia Pacific Primary Biliary Cirrhosis Drug Sales Market Share by Country (2021-2032) Figure 43. China Primary Biliary Cirrhosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 44. Japan Primary Biliary Cirrhosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 45. South Korea Primary Biliary Cirrhosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 46. Southeast Asia Primary Biliary Cirrhosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 47. India Primary Biliary Cirrhosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 48. Australia Primary Biliary Cirrhosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 49. South America, Middle East and Africa Primary Biliary Cirrhosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 50. South America, Middle East and Africa Primary Biliary Cirrhosis Drug Sales Market Share by Country (2021-2032) Figure 51. Brazil Primary Biliary Cirrhosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 52. South Africa Primary Biliary Cirrhosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 53. Saudi Arabia Primary Biliary Cirrhosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 54. Turkey Primary Biliary Cirrhosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 55. Argentina Primary Biliary Cirrhosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 56. UAE Primary Biliary Cirrhosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 57. Egypt Primary Biliary Cirrhosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 58. Chile Primary Biliary Cirrhosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 59. Global Primary Biliary Cirrhosis Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Primary Biliary Cirrhosis Drug Revenue (2021-2032) & (US$ Million) Figure 62. North America Primary Biliary Cirrhosis Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Primary Biliary Cirrhosis Drug Revenue (2021-2032) & (US$ Million) Figure 64. Europe Primary Biliary Cirrhosis Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Primary Biliary Cirrhosis Drug Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Primary Biliary Cirrhosis Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Primary Biliary Cirrhosis Drug Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Primary Biliary Cirrhosis Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Primary Biliary Cirrhosis Drug Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Primary Biliary Cirrhosis Drug Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Budesonide
  • NGM-282
  • MBX-8025
  • GSK-2330672
  • FFP-104
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • AlbireoPharma
  • CymaBay Therapeutics, Inc.
  • Dr. Falk Pharma GmbH
  • Enanta Pharmaceuticals, Inc.
  • Intercept Pharmaceuticals, Inc.
  • MediGene AG
  • NGM Biopharmaceuticals, Inc.
  • Virobay Inc.
  • GlaxoSmithKline Plc
  • Johnson & Johnson

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Primary Biliary Cirrhosis Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Primary Biliary Cirrhosis Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Primary Biliary Cirrhosis Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Primary Biliary Cirrhosis Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Primary Biliary Cirrhosis Drug Market Dynamics
  1. 2.1 Primary Biliary Cirrhosis Drug Industry Trends
  2. 2.2 Primary Biliary Cirrhosis Drug Industry Drivers
  3. 2.3 Primary Biliary Cirrhosis Drug Industry Opportunities and Challenges
  4. 2.4 Primary Biliary Cirrhosis Drug Industry Restraints
3 Primary Biliary Cirrhosis Drug Market by Manufacturers
  1. 3.1 Global Primary Biliary Cirrhosis Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Primary Biliary Cirrhosis Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Primary Biliary Cirrhosis Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Primary Biliary Cirrhosis Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Primary Biliary Cirrhosis Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Primary Biliary Cirrhosis Drug Manufacturers, Product Type & Application
  7. 3.7 Global Primary Biliary Cirrhosis Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Primary Biliary Cirrhosis Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Primary Biliary Cirrhosis Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Primary Biliary Cirrhosis Drug Tier 1, Tier 2, and Tier 3
4 Primary Biliary Cirrhosis Drug Market by Type
  1. 4.1 Primary Biliary Cirrhosis Drug Type Introduction
  2. 4.1.1 Budesonide
  3. 4.1.2 NGM-282
  4. 4.1.3 MBX-8025
  5. 4.1.4 GSK-2330672
  6. 4.1.5 FFP-104
  7. 4.1.6 Others
  8. 4.2 Global Primary Biliary Cirrhosis Drug Sales by Type
  9. 4.2.1 Global Primary Biliary Cirrhosis Drug Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Primary Biliary Cirrhosis Drug Sales by Type (2021-2032)
  11. 4.2.3 Global Primary Biliary Cirrhosis Drug Sales Market Share by Type (2021-2032)
  12. 4.3 Global Primary Biliary Cirrhosis Drug Revenue by Type
  13. 4.3.1 Global Primary Biliary Cirrhosis Drug Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Primary Biliary Cirrhosis Drug Revenue by Type (2021-2032)
  15. 4.3.3 Global Primary Biliary Cirrhosis Drug Revenue Market Share by Type (2021-2032)
5 Primary Biliary Cirrhosis Drug Market by Application
  1. 5.1 Primary Biliary Cirrhosis Drug Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Primary Biliary Cirrhosis Drug Sales by Application
  6. 5.2.1 Global Primary Biliary Cirrhosis Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Primary Biliary Cirrhosis Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Primary Biliary Cirrhosis Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Primary Biliary Cirrhosis Drug Revenue by Application
  10. 5.3.1 Global Primary Biliary Cirrhosis Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Primary Biliary Cirrhosis Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Primary Biliary Cirrhosis Drug Revenue Market Share by Application (2021-2032)
6 Global Primary Biliary Cirrhosis Drug Sales by Region
  1. 6.1 Global Primary Biliary Cirrhosis Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Primary Biliary Cirrhosis Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Primary Biliary Cirrhosis Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Primary Biliary Cirrhosis Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Primary Biliary Cirrhosis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Primary Biliary Cirrhosis Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Primary Biliary Cirrhosis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Primary Biliary Cirrhosis Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Primary Biliary Cirrhosis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Primary Biliary Cirrhosis Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Primary Biliary Cirrhosis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Primary Biliary Cirrhosis Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Primary Biliary Cirrhosis Drug Revenue by Region
  1. 7.1 Global Primary Biliary Cirrhosis Drug Revenue by Region
  2. 7.1.1 Global Primary Biliary Cirrhosis Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Primary Biliary Cirrhosis Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Primary Biliary Cirrhosis Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Primary Biliary Cirrhosis Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Primary Biliary Cirrhosis Drug Revenue (2021-2032)
  8. 7.2.2 North America Primary Biliary Cirrhosis Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Primary Biliary Cirrhosis Drug Revenue (2021-2032)
  11. 7.3.2 Europe Primary Biliary Cirrhosis Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Primary Biliary Cirrhosis Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Primary Biliary Cirrhosis Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Primary Biliary Cirrhosis Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Primary Biliary Cirrhosis Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 AlbireoPharma
  2. 8.1.1 AlbireoPharma Company Information
  3. 8.1.2 AlbireoPharma Business Overview
  4. 8.1.3 AlbireoPharma Primary Biliary Cirrhosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 AlbireoPharma Primary Biliary Cirrhosis Drug Product Portfolio
  6. 8.1.5 AlbireoPharma Recent Developments
  7. 8.2 CymaBay Therapeutics, Inc.
  8. 8.2.1 CymaBay Therapeutics, Inc. Company Information
  9. 8.2.2 CymaBay Therapeutics, Inc. Business Overview
  10. 8.2.3 CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Product Portfolio
  12. 8.2.5 CymaBay Therapeutics, Inc. Recent Developments
  13. 8.3 Dr. Falk Pharma GmbH
  14. 8.3.1 Dr. Falk Pharma GmbH Company Information
  15. 8.3.2 Dr. Falk Pharma GmbH Business Overview
  16. 8.3.3 Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Product Portfolio
  18. 8.3.5 Dr. Falk Pharma GmbH Recent Developments
  19. 8.4 Enanta Pharmaceuticals, Inc.
  20. 8.4.1 Enanta Pharmaceuticals, Inc. Company Information
  21. 8.4.2 Enanta Pharmaceuticals, Inc. Business Overview
  22. 8.4.3 Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Portfolio
  24. 8.4.5 Enanta Pharmaceuticals, Inc. Recent Developments
  25. 8.5 Intercept Pharmaceuticals, Inc.
  26. 8.5.1 Intercept Pharmaceuticals, Inc. Company Information
  27. 8.5.2 Intercept Pharmaceuticals, Inc. Business Overview
  28. 8.5.3 Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Portfolio
  30. 8.5.5 Intercept Pharmaceuticals, Inc. Recent Developments
  31. 8.6 MediGene AG
  32. 8.6.1 MediGene AG Company Information
  33. 8.6.2 MediGene AG Business Overview
  34. 8.6.3 MediGene AG Primary Biliary Cirrhosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 MediGene AG Primary Biliary Cirrhosis Drug Product Portfolio
  36. 8.6.5 MediGene AG Recent Developments
  37. 8.7 NGM Biopharmaceuticals, Inc.
  38. 8.7.1 NGM Biopharmaceuticals, Inc. Company Information
  39. 8.7.2 NGM Biopharmaceuticals, Inc. Business Overview
  40. 8.7.3 NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Portfolio
  42. 8.7.5 NGM Biopharmaceuticals, Inc. Recent Developments
  43. 8.8 Virobay Inc.
  44. 8.8.1 Virobay Inc. Company Information
  45. 8.8.2 Virobay Inc. Business Overview
  46. 8.8.3 Virobay Inc. Primary Biliary Cirrhosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Virobay Inc. Primary Biliary Cirrhosis Drug Product Portfolio
  48. 8.8.5 Virobay Inc. Recent Developments
  49. 8.9 GlaxoSmithKline Plc
  50. 8.9.1 GlaxoSmithKline Plc Company Information
  51. 8.9.2 GlaxoSmithKline Plc Business Overview
  52. 8.9.3 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Product Portfolio
  54. 8.9.5 GlaxoSmithKline Plc Recent Developments
  55. 8.10 Johnson & Johnson
  56. 8.10.1 Johnson & Johnson Company Information
  57. 8.10.2 Johnson & Johnson Business Overview
  58. 8.10.3 Johnson & Johnson Primary Biliary Cirrhosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Johnson & Johnson Primary Biliary Cirrhosis Drug Product Portfolio
  60. 8.10.5 Johnson & Johnson Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Primary Biliary Cirrhosis Drug Value Chain Analysis
  2. 9.1.1 Primary Biliary Cirrhosis Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Primary Biliary Cirrhosis Drug Production Mode & Process
  6. 9.2 Primary Biliary Cirrhosis Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Primary Biliary Cirrhosis Drug Distributors
  9. 9.2.3 Primary Biliary Cirrhosis Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst